CRYSTALLINE FORMS OF ATORVASTATIN 4-(NITROOXY) BUTYL ESTER
    10.
    发明申请
    CRYSTALLINE FORMS OF ATORVASTATIN 4-(NITROOXY) BUTYL ESTER 审中-公开
    4-(硝基)丁酯酯的结晶形式

    公开(公告)号:US20100152274A1

    公开(公告)日:2010-06-17

    申请号:US12594511

    申请日:2008-03-19

    CPC分类号: C07D207/34

    摘要: The present invention relates to two crystalline forms designated as form A and form B, of (βR,δR)-2(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbon-yl]-1H-pyrrole-1-heptanoic acid 4-(nitrooxy)butyl ester (atorvastatin 4-(nitrooxy)butyl ester), represented by the formula (I), The invention also relates to processes for the preparation of the forms A and B, to pharmaceutical compositions comprising the two forms, and to their use for treating and/or preventing acute coronary syndromes, stroke, neurodegenerative disorders, such as Alzheimer's and Parkinson's disease as well as autoimmune diseases, such as multiple sclerosis.

    摘要翻译: 本发明涉及两种结晶形式,其命名为(&bgr; R,δR)-2(4-氟苯基) - ,b-,δ-二羟基-5-(1-甲基乙基)-3-苯基的形式A和形式B -4 - [(苯基氨基)碳基] -1H-吡咯-1-庚酸4-(硝基氧基)丁酯(阿托伐他汀4-(硝基氧基)丁酯),由式(I)表示,本发明还涉及 用于制备形式A和B的方法,包含两种形式的药物组合物及其用于治疗和/或预防急性冠状动脉综合征,中风,神经变性疾病如阿尔茨海默病和帕金森病以及自身免疫疾病的用途 ,如多发性硬化症。